Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.64 |
| ▸ | MAOA | P21397 | 3/20 | 0.64 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.59 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | STAT1 | P42224 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.54 |
| ▸ | MMP1 | P03956 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | MMP12 | P39900 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6306364 | 0.85 | MAOB (0.62) | MAOBMAOANR4A2PARP10KDM4E | |
| SCHEMBL7373666 | 0.84 | ALDH1A1 (0.61) | MAOBNR4A2PARP10RAB9A | |
| SCHEMBL6306323 | 0.83 | NR4A2 (0.70) | MAOBMAOANR4A2PARP10 | |
| SCHEMBL4424360 | 0.81 | MAOB (0.80) | MAOBMAOANR4A2PARP10MRGPRX4 | |
| SCHEMBL2989798 | 0.78 | MAOB (0.57) | MAOBMAOANR4A2PARP10MRGPRX4 | |
| SCHEMBL5875467 | 0.77 | NR4A2 (0.65) | MAOBMAOANR4A2PARP10 | |
| SCHEMBL12998987 | 0.77 | NR4A2 (0.65) | MAOBMAOANR4A2PARP10MRGPRX4 | |
| SCHEMBL12998983 | 0.77 | NR4A2 (0.65) | MAOBMAOANR4A2PARP10MRGPRX4 | |
| SCHEMBL4427972 | 0.77 | MAOB (0.71) | MAOBMAOANR4A2PARP10 | |
| SCHEMBL6440009 | 0.76 | NR4A2 (0.53) | MAOBMAOANR4A2PARP10MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539694-A1 | 2,3-DIHYDRO-ISOINDOL-1-ONES WITH MAO-B INHIBITING ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-15 | — | — | EP | disclosed |
| US-6846832-B2 | 2,3-dihydro-isoindol-1-one derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-01-25 | — | — | US | disclosed |
| US-20040082603-A1 | 2,3-Dihydro-isoindol-1-one derivatives | HOFFMANN-LA ROCHE INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2004014856-A1 | 2,3-DIHYDRO-ISOINDOL-1-ONES WITH MAO-B INHIBITING ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082603-A1 | 2,3-Dihydro-isoindol-1-one derivatives | MAOB, MAOA, COMT | MAOB 1/4885MAOA 2/4885NR4A2 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.